This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignees: Avid Radiopharmaceuticals, Inc., University of Michigan, University of Pennsylvania. Active years: 2013.
Company Filing History:
1 out of 2 
1 out of 3,523 
1 out of 2,651 
Years Active: 2013
Title: Michael Kilbourn - Innovator in Imaging Agents
Introduction
Michael Kilbourn is a prominent inventor based in Ann Arbor, Michigan. He is recognized for his significant contribution to the field of radiopharmaceuticals, specifically in imaging agents for medical applications. With one patent to his name, Kilbourn's work has impacted the ability to monitor diseases related to vesicular monoamine transporters.
Latest Patents
Kilbourn's notable patent is titled "Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents." This invention focuses on a groundbreaking method of imaging vesicular monoamine transporters. The patent encompasses labeled compounds and pharmaceutical compositions that aid in the development of methods for creating these labeled compounds. It also includes innovative approaches for monitoring the progression of diseases associated with vesicular monoamine transporters.
Career Highlights
Kilbourn has had a distinguished career, having worked at prestigious institutions such as the University of Pennsylvania and the University of Michigan. His experience in these renowned universities has contributed to his expertise in the development of imaging technologies and radiolabeled compounds.
Collaborations
Throughout his career, Michael Kilbourn has collaborated with esteemed colleagues including Hank F Kung and Mei-Ping Kung. These collaborations have fostered significant advancements in the field, further enhancing the application of his patented inventions.
Conclusion
Michael Kilbourn's contributions to the world of medical imaging through his innovative patent showcase the importance of research and development in understanding complex diseases. His journey through respected institutions and collaborations exemplifies the spirit of innovation that drives progress in the field of radiopharmaceuticals.